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Abstract
Placental neurokinin B appears to be post-translationally modiﬁed by phosphocholine (PC) attached to the aspartyl side
chain at residue 4 of the mature peptide. Corticotrophin releasing factor (CRF) was found to be expressed by the rat
placenta with the main secreted forms being phosphocholinated proCRFC/K one or two polysaccharide moieties. A
combination of high-pressureliquid chromatography (HPLC) and two-site immunometric analysis suggested that PC was
also attached to the placental precursors of adrenocorticotrophin, hemokinin, activin and follistatin. However, the fully
processed forms of rat placental activin and CRF were free of PC. Formerly, the parasitic ﬁlarial nematodes have used
PC as a post-translational modiﬁcation, attached via the polysaccharide moiety of certain secretory glycoproteins to
attenuatethe hostimmunesystemallowingparasitesurvival,but itis thePC groupitselfwhichendowsthecarrier withthe
biological activity. The fact that treatment of proCRF peptides with phospholipase C but not endoglycosidase destroyed
PC immunoreactivity suggested a simpler mode of attachment of PC to placental peptides than that used by nematodes.
Thus, it is possible that by analogy the placenta uses its secreted phosphocholinated hormones to modulate the mother’s
immune system and help protect the placenta from rejection.
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Introduction
The placenta is known to control the mother’s
metabolism for the beneﬁt of the foetus often, as in
pre-eclampsia, to the mother’s detriment. In this, it is
comparable to parasites which have also evolved
sophisticated mechanisms to control the host, including
manipulation of immune surveillance allowing parasitic
survival (Harnett & Harnett 1993). The fact that the
developing placenta is capable of producing signiﬁcant
concentrations of chorionic gonadotrophin (Brody &
Carlstrom 1962) and placental lactogen (Kaplan et al.
1968, Saxenaet al. 1968),isa testament toits ability to act
asanefﬁcientendocrineorgan,butalthoughthemRNAs
of many other peptide and protein hormones can be
found in placental extracts, there are only a few reports
of signiﬁcant concentrations of translated products in
maternal blood (for review, see Krieger 1982).
Two good examples are the neuropeptides cortico-
trophin releasing factor (CRF) and neurokinin B
(NKB), both of which are synthesised and secreted
by the human placenta reaching nanomolar
concentrations in maternal blood in certain patho-
logical conditions, such as pre-eclampsia (NKB (Page
et al. 2000), CRF (Campbell et al. 1987, Florio et al.
2004)) and pre-term labour (CRF (Campbell et al. 1987,
Mclean et al. 1995)). Formerly, the low abundance of
these neuropeptide hormones found in placental tissue
extracts has made their complete chemical character-
isation difﬁcult, but now modern mass spectrometrical
technology should have made this achievable.
During an attempt to isolate and characterise human
NKB from term human placentae (using preparative C3
HPLC, gel ﬁltration and microbore C8 HPLC), we
detected a number of abundant co-purifying substances
in the molecular mass range 900–1300 kDa (cf. brain
NKB 1209 kDa) that, when subjected to TOF–TOF (time
of ﬂight–time of ﬂight) mass spectrometry (Bruker
UltraFLEX, Bruker Daltonics Limited, Coventry, UK)
fragmentedtostrongmassionsignalsof184and104 kDa,
consistent with those of phosphocholine (PC) and
choline respectively. As these PC-containing substances
did not just coincidewith the immunoreactive NKB peak
fractions inthe ﬁnalpuriﬁcationstep, we concluded that
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may have been formed during autolysis of other
PC-containing peptides/proteins in the term human
placenta.Inmammals,PCisnormallyattachedtoglycerol
as part of phosphatidylcholine and constitutes an
important part of the membrane complex (Vance
1990). However, protein-/peptide-bound PC has been
found only as part of complex N-linked polysaccharide
post-translational modiﬁcation (PTM) found on certain
(parasitic) ﬁlarial nematodesecretoryproteins whichare
used to attenuate the host immune response (Haslam et
al. 1997). The immunomodulatory properties of this PC
group relate to its capacity to inhibit B- and T-cell
activation and promote a Th2-type rather than a Th1-
type immune response (Harnett et al. 2003), which are
generally associated with protection. Indeed, helminth
nematode infectionhasthecapacitytopromoteallograft
survival through the induction of type 2 immunity
development and inhibition of allospeciﬁc cytotoxic
T-lymphocyte activity (Liwski et al. 2000). The carrier
protein and the mode of attachment of PC does not
appear to be important in this respect, as PC coupled
directly to BSA can mimic the attenuating effect on the
immune system (Harnett & Harnett 1993). This paper
describes the discovery of this novel mammalian PTM
attachedto a number ofplacentalhormones and reviews
the implications in human physiology and disease.
Although it was generally accepted that CRF expression
wasconﬁnedtoprimateplacentae(Robinsonetal.1989),
another unexpected ﬁnding of this study was the
signiﬁcant concentrations of immunoreactive CRF and
proCRF peptides in rat placental and plasma extracts.
Materials and methods
Rationale behind the use of afﬁnity puriﬁed antibodies
The reason for generating in-house high afﬁnity puriﬁed
immunoglobulins is that their use minimises the chance
ofnon-speciﬁccross-reactions.InPAGEimmunoblots,we
compared the results between immunoglobulin Gs
(IgGs) afﬁnity puriﬁed on different epitopes to counter-
act any possibility of false positives and facilitate
identiﬁcation. The two-site immunoassay technique
which needs both epitopes to be occupied in the analyte
to give a signal is thus even less prone to giving non-
speciﬁc reactions and relies on an equivalent amount of
each IgG binding in a stoichiometric reaction to the
relative epitope (the initial reaction mixture contains
both IgGs in excess). In the immunometric assay,
interference in complex formation gives rise to negative
readings, in contrast to classical immunoassays where
perturbation of the equilibrium will give rise to false
positives. Although we did not have any PC-containing
neuropeptides to use as standards in our immunometric
assays, itwouldbeexpected thatthe stoichiometry would
ensure similar ELISA readouts as the preparation of all
afﬁnity IgGs was similar. The coincidence of readouts
aroundchromatographicpeakswhencomparingthetwo-
sitepeptide/peptideimmunometricassayresultswiththe
respective peptide/PC results is evidence that the
technology is providing the expected speciﬁcity. Proxi-
mity of bulky N-linked polysaccharide moieties attached
near antibody epitopes (either peptide or PC) would
stereochemically hinder the binding of the relevant IgG.
Multiple PC PTMs attached to the same peptide
backbone would result in an equivalent amount of
bound biotinylated anti-PC IgG thus increasing the ﬁnal
signal respectively in an anti-PC/anti-peptide assay over
the result from an anti-peptide/anti-peptide immunoas-
say. The anti-PC/anti-PC two-site assay would only detect
peptides/proteins containing more than one PC PTM
available for binding the anti-PC IgG.
Antisera production and IgG afﬁnity puriﬁcation
Apart from the commercial RIA used in our original
NKB study (Page et al. 2000) all other assays were
generated in house.
NKB(1–5)-Cys-NH2 and hemokinin (1–5)-Cys-NH2
were coupled to ‘puriﬁed protein derivative’ (Vet Labs
Agency, Surrey, UK) which had been derivatised with
4-maleimidobutyric acid N-hydroxysuccinimide ester
(Sigma). NKB (6–10) was coupled to the same protein
with glutaraldehyde. PC-KLH was purchased from
Biosearch Tech Inc., Novato, CA, USA. Antisera were
raised in sheep by monthly injections of immunogen
(100 mg) emulsiﬁed in Freund’s adjuvant.
Anti-PC IgG was afﬁnity puriﬁed on p-aminophenyl-
phosphorylcholine solid phase (Perbio Science UK Ltd,
Cramlington, Northumberland), anti-hemokinin(1–5),
anti-NKB (1–5) were afﬁnity puriﬁed on the respective
peptide coupled through the C-terminal cysteine to
iodoacetyl gel (Perbio Science UK Ltd). Anti-
NKB(6–10) sheep immunoglobulins were afﬁnity pur-
iﬁed on the same peptide coupled to cyanogen
bromide-activated Sepharose. Bound antibodies were
eluted using 50 mM sodium acetate/formate buffers
containing 20% (v/v) acetonitrile with a pH gradient
from 6 to 3. Acetonitrile was removed using a vacuum
concentrator. The anti-inhibin/activin bA-subunit
antibodies (Knight et al. 1996) and the production of
anti-proCRF(1–21) and anti-CRF(21–41) IgGs have
been described previously (Sanderson et al. 2000).
Acid extraction of and puriﬁcation of placental
peptides
Human term placentae were obtained with consent
after full explanation of the purpose and nature of all
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pregnancy) were obtained from time-mated Wistar rats
(Charles River UK Limited, Kent, UK), caged and
maintained as required by the United Kingdom
Animals (Scientiﬁc Procedures) Act 1986. Tissues
were rinsed in saline and homogenised at 4 8C in ten
volumes (w/v) of acid extraction buffer (1 M HCl
containing 5% (v/v) formic acid, 1% (w/v) NaCl, 1%
(v/v) triﬂuoroacetic acid (TFA) and 0.1% (v/v)
b-mercaptoethanol). After centrifugation (34 500 g,
4 8C), the supernatant was loaded onto a Sep-Pak C18
cartridge (Waters, Milford, MA, USA) and washed with
0.1% (v/v) TFA. Peptides were eluted with 0.1% (v/v)
TFA containing 80% (v/v) acetonitrile and then dried
in a vacuum centrifuge with 1 mg mannitol. Peptides
were resuspended in water before use.
A Sep-Pak extract equivalent to 100 g rat placentae or
whole human placenta was subjected to preparative
reverse phase HPLC using a Hi-bore RP-318 C3
10 mm!250 mm column (Bio-Rad). Peptides were
eluted with a gradient of 10–60% aqueous aceto-
nitrile/0.1% (v/v) TFA at a ﬂow rate of 2.5 ml/min.
Fractions (0.5 min) were dried by vacuum centrifuge
with 1 mg mannitol before resuspending in 100 mlo f
20 mM HCl. Samples were freeze-dried over NaOH
pellets (to exchange protein TFA
K for Cl
K to render
them more water soluble) and then resuspended in
50 ml nuclease/protease-free water.
Placental NKB was further puriﬁed by gel ﬁltration
on Superdex-peptide column (Amersham) equili-
brated with 0.1% (v/v) TFA/20% (v/v) acetonitrile at
a ﬂow rate of 0.25 ml/min, followed by microbore
HPLC (1!150 mm C8 Vydac column run at 70 ml/min
with a gradient 0.1% (v/v) TFA/10% (v/v) acetonitrile
to 0.1%TFA (v/v)/60% (v/v) acetonitrile). Fractions
(w40 ml) were hand collected.
Digestion with Asp-N protease
Puriﬁed NKB or synthetic NKB was diluted into 500 ml
assay buffer (0.05 M phosphate buffer (pH 7.5) 0.1%
BSA 0.02% thiomerosal) to a concentration of 1 ng/ml.
After addition of 1 U Asp-N endoprotease (Calbiochem
Endoprotease Asp-N excision grade Pseudomonas fragi),
the mixture was incubated for 2 h at 37 8C. The
mixtures were then assayed in duplicate in the two-site
NKB immunometric assay (see below).
ELISA protocol
Afﬁnity puriﬁed IgG fractions were either coated
directly (200 ng/100 mlo f0 . 1 MN a C O 3 per well
incubated overnight (o/n) on Nunc-maxisorb immu-
noplate F96; the capture antibody) or biotinylated
using biotinamido-caproate-n-hydroxyl succinamide
ester; the second site antibody. Before use, coated
plates were blocked o/n (50 mM PO4 buffer (pH 7.4),
5% (w/v) BSA and 0.02% (w/v) thimerosal) and
washed (50 mM Tris-buffered saline (pH 7.5)
containing 0.05% (v/v) Tween 20 and 0.02% (w/v)
thimerosal (TBST)). After incubating o/n with 100 ml
sample diluted in assay buffer (50 mM PO4 buffer (pH
7.4), 0.5% (w/v) BSA and 0.02% (w/v) thimerosal), the
plates were washed and then incubated with the second-
site biotinylated antibody for 4 h at RT (100 ng/well).
After washing, streptavidin-linked alkaline phosphatase
(Sigma) was added (100 ml/well; 1:10 000 in TBST) and
incubated for 2 h at RT. Following washing, bound
alkaline phosphatase was detected using para-nitrophe-
nyl phosphate (200 ml/well; Sigma). After 20 min at RT
the reaction was stopped by addition of 2 M NaOH
(50 ml/well). Absorbance was read at 405 nm (refer-
ence wavelength 650 nm) using a microplate reader
(Emax; Molecular Devices Ltd, Berks, UK). proCRF
immunometric assay used antibodies to extreme N- and
C-terminal epitopes in the 161 residue precursor, anti-
proCRF(1–21) and anti-CRF(21–41) or proCRF
140–161, the NKB/NKB assay used an anti-
NKB(1–5))/anti-NKB(6–10) combination, activin A,
as reported previously (Knight et al. 1996) and the
hemokinin assay used anti-HK(1–5)/anti- NKB (6–10).
Anti-PC western immunoblot
Random HPLC fractions from the C3 HPLC of the rat
placentalextractwereresolvedbySDS-gelelectrophoresis
on 16% polyacrylamide tris/tricine gels in reducing
conditions and transferred by electroblotting on to
polyvinylidene diﬂouride (PVDF). Membranes were
blockedovernightinTBSTcontaining4%BSA.Immuno-
blottingwasperformedbyincubatingthemembranewith
afﬁnity puriﬁed biotinylated anti-PC-antibody (50 ng/ml
in TBST containing 0.5% (w/v) BSA). Biotinylated
antibodies were localised using steptavidin-HRP and
visualised with Amersham Pharmacia Biotech ECL
Western blotting Detection System in accordance with
the manufacturer’s instructions.
Preparation of anti-CRF Sepharose and puriﬁcation of
CRF containing peptides
Afﬁnity puriﬁed anti-CRF (21–41) IgG was coupled to
cyanogen bromide activated Sepharose (8 mg
IgG/1.5 ml Sepharose gel per column) in 100 mM
HEPES buffer (pH 8), mixed o/n at 4 8C, blocked by
the addition of 1 M ethanolamine/HCl and then
washed in 100 mM HEPES buffer (pH 8).
Plasma or placenta were obtained from pregnant rats
(Day 20 of pregnancy; nZ10 per group). Plasma
was pooled (17 ml) and placental tissue was acidiﬁed
Phosphocholination of placental polypeptides . T M LOVELL and others 191
www.endocrinology-journals.org Journal of Molecular Endocrinology (2007) 39, 189–198and Sep-Pak extracted, and subjected to reverse phase
HPLC as described above before being pooled.
Separate plasma and placenta pools were made up to
a ﬁnal concentration of 100 mM HEPES (pH 8) before
being mixed separately with 1.5 ml anti-CRF IgG
Sepharose o/n at 4 8C. Each IgG/Sepharose gel
preparation was packed separately into columns and
washed with 30 ml of 100 mM HEPES/0.01% (v/v)
triton X-100, 30 ml of 100 mM HEPES, 6 ml of 0.5 M
ammonium acetate containing 20% (v/v) acetonitrile
(high salt wash) and 6 ml water/20% (v/v) acetonitrile.
Bound CRF-containing peptides were eluted in 0.1%
(v/v) formic acid/20% (v/v) acetonitrile (1 ml frac-
tions). Acetonitrile was then removed using a vacuum
centrifuge. The eluted CRF peptides were resolved by
SDS-PAGE and immunoblotted as described in anti-PC
western immunoblot utilising afﬁnity puriﬁed biotiny-
lated anti-PC, anti-CRF or anti-proCRF antibodies
(50 ng/ml in TBST containing 0.5% (w/v) BSA).
Enzymatic treatment of placental pro-CRF and activin
A( bA–bA dimer)
In Fig. 4, fractions 36–37 (peak one) and fractions
41–43 (peak two) containing proCRF-PC and pro-bA-
PC immunoreactivity were pooled individually. To wells
of anti-proCRF (or anti-bA)-coated plates, 100 ml
sample was added and incubated overnight. After
washing, plate wells were subjected to overnight
digestion at 37 8C with either phospholipase C (Bacillus
cereus PLC; Calbiochem) at 3 units/well in 10 mM Tris
(pH 8) containing 150 mM NaCl, 5 mM CaCl2, 0.1%
(v/v) Triton X-100 and 0.05% (v/v) BSA or with an
enzymatic protein deglycosylation cocktail (Sigma;
E_DEGLY; equivalent to 0.2 ml each enzyme per well
in 50 mM phosphate buffer containing 0.1% (w/v)
SDS, 50 mM b-mercaptoethanol and 0.75% (v/v) Triton
X-100). Plates were then washed and treated as Day 2 of
the anti-proCRF/anti-PC ELISA (or anti-bA/anti-PC
ELISA). Anti-proCRF/anti-CRF and activin A ELISAs
were run as controls for proteolytic interference.
Results
When human placental extracts were submitted to gel
ﬁltration (Superdex-peptide) and the resulting frac-
tions were monitored with the NKB RIA used in our
earlier study (Page et al. 2000), the immunoreactivity
consistently eluted as a single peak with a Kav of 0.45
when compared with 0.48 for synthetic/brain NKB
suggesting that the placental form was slightly larger
than that found in neural tissue. Successive puriﬁcation
of this placental NKB by preparative C3 HPLC, gel
ﬁltration and ﬁnally microbore C8 HPLC resulted in
peak fractions with absorbance readings in the
NKB/NKB ‘two-site’ immunometric assay of 0.30, 0.73
and 0.39 when compared with those of 0.27, 0.71 and
0.38 in the PC/NKB ‘two-site’ immunometric assay. The
close coincidence of the results in each assay of such
puriﬁed material would suggest that the same peptide is
being measured in both assays and thus the small
increase in molecular size of placental NKB appears to
be caused by PTM by PC. The immunoreactivity of this
same puriﬁed placental NKB (monitored by the NKB/
NKB ‘two-site’ assay) wasresistant (11% loss after2 h)to
proteolytic digestion with AspN, whereas the immunor-
eactivity of synthetic NKB was as expected largely
destroyed (75% loss) by the same treatment. As AspN
cuts peptide chains before aspartyl residues and the
N-terminal NKB IgG used in this assay had been afﬁnity
puriﬁed on NKB(1–3) attached to solid phase, this
result suggests that the PC modiﬁcation was on the side
group of the aspartyl residue at position 4 of placental
NKB (Asp-Met-His-Asp
(wPC)-Phe-Phe-Val-Gly-Leu-Met-
NH2) and was responsible for reducing the activity of
the protease at its target residue by altering the
chemical character of the side chain.
The PC modiﬁcation also seemed to be present on
proCRF. Mature rat proCRF is a 161 residue peptide
(human proCRF is a 170mer) with CRF comprising the
last41residues(121–161intheratand130–170inhuman
proCRF). Figure 1a shows the results of several ‘two-site’
immunometric assays of Sep-Pak extracts of human and
rat placentae (Fig. 1b depicts the epitopes in proCRF of
the antibodies used in this study). Despite the previous
report of the absence of CRF mRNA in the rat placenta
(Robinson et al. 1989) there was clear evidence of
immunoreactive full-length proCRF detected by the
anti-proCRF(1–21)/anti-CRF two-site assay in rat placen-
tal extracts. A strong signal was also found in the two-site
immunometric assay using an anti-proCRF(1–21) IgG
combined with the anti-PC IgG in both human and rat
placental extracts suggesting that there was more than
one PC attached to proCRF. As the anti-proCRF/anti-PC
assay did not appear to detect signiﬁcant reactivity in
brainextracts,thissuggeststhatPCisattachedasaPTMto
proCRF predominantly in the placenta. The strong
positive result with the anti-PC/anti-PC assay suggests
that there may be other placental products than proCRF
thatcontainmorethanonePCasaPTM.Therewasslight
evidence,however,forotherphosphocholinatedmaterial
in rat brain extracts. Because the presence of CRF
immunoreactivity in the rat placenta was unexpected we
decided to explore it further.
The results of Sep-Pak rat placental and plasma
extracts (after afﬁnity puriﬁcation on solid phase anti-
CRF IgG) submitted to SDS-PAGE and immunoblotted
with afﬁnity puriﬁed anti-CRF, anti-proCRF(1–21) and
anti-PC IgGs are shown in Fig. 2. As all these materials
should carry the CRF epitope, the only CRF-immuno-
reactive band which did not cross-react with the anti-PC
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ing mature CRF. When the same starting extract was
submitted to gel ﬁltration on Superdex 75 this CRF
band eluted in the same position as synthetic CRF.
Thereisclearevidenceforanumberoflargemolecular
weight proCRF bands in both placenta and plasma
immunoblots which also reacted with the anti-PC IgG.
A 15 kDa band is present in all three tracks of both
placental and plasma extract immunoblots. As this
15 kDa band cross-reacts with afﬁnity puriﬁed IgGs to
the extreme N- and C-terminal eptitopes of mature
proCRF(residues1–21and161–181seeFig.1b),andalso
with the anti-PC IgG, it must represent mature (non-
glycosylated) phosphocholinated rat proCRF. It is
difﬁcult to predict what effect a highly charged zwitter-
ionic group suchasPChas onthe mobility inSDS-PAGE,
but as mature proCRF has a predicted molecular mass of
17.8 kDa it would appear that this particular propeptide
Figure 1 (a) Detection of proCRF, PC-containing proCRF and PC/PC-containing material in rat (day 20 of
pregnancy)and human(term) placentaland ratbrain extracts. Openhistogramsarethe ELISAresults from
the proCRF/CRF two-site immunometric assay, black proCRF/PC assay and grey PC/PC assay. Data
plotted are the means of duplicate determinations. (b) Diagram depicts the structure of proCRF and the
epitopes of the antibodies used in this study.
Figure 2 Afﬁnity puriﬁed rat (a) placenta and (b) plasma CRF-
immunoreactive material subjected to SDS-PAGE. Western
tracks were immunobloted separately with either anti-PC-, anti-
CRF- or anti-proCRF- IgGs (Fig. 1b).
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slightly faster running band than the 15 kDa band in the
anti-CRF and anti-proCRF tracks in the placental extract
blots (Fig. 2a), which is not present in the anti-PC track
suggesting that PC modiﬁcation may have a small effect
on the SDS-PAGE electromobility. The pattern of bands
in the placental extract immunoblot also appears to be
more complex suggesting the presence of other proces-
sing intermediates which are not present in rat plasma
where the pattern observed would be representative of
the ﬁnal secreted forms. As rat proCRF contains two
consensus motifs for N-linked polysaccharide moiety
attachment (at asparaginyl residues 47 and 57) and the
15 kDa band represents non-glycosylated phophocholi-
nated proCRF, any larger molecular weight band would
be caused by glycosylation. In the plasma extract
immunoblot (Fig. 2b), the reduced intensity of the
30 kDa vs 25 kDa bands in the anti-proCRF(1–21) and
anti-PC tracks when compared with the anti-CRF track
suggests that the proximity of two bulky polysaccharide
moieties (attached at residues 47 and 57) has a greater
steric hindrance effect on antibody binding to the more
proximate proCRF (1–21) and PC epitopes than to the
CRFepitopepresentattheextremeC-terminalofproCRF
(residues 141–161). The fact that all secreted proCRF
bands are PC immunoreactive suggests that phophocho-
lination modiﬁcation in the placenta is complete,
whereas glycosylation is only partial.
As a number of other neuropeptide antibody/PC
antibody combination peptide/peptide peptide/PC
assays for precursor hormones, such as proNKB, prohe-
mokinin, proopiomelanocortin, follistatin and pro-acti-
vinA,suggestedthattheseprecursorsalsocarriedPCasa
PTM, placental extracts were submitted to preparative
reverse-phaseHPLCandtheresultingfractionssubjected
to SDS-PAGE and anti-PC immunoblotting (Fig. 3). It is
clear from the multiple bands resulting from this
experiment that placental extracts contain a large
number of polypeptides and proteins that have PC
attached. Assaying the same HPLC fractions with the
speciﬁc two-site assays indicated that all the placental
polypeptide precursors measured, including most pro-
cessed intermediates had PC attached as indicated by a
high degree of coincidence of immunoreactive peaks in
peptide/peptide versus peptide/PC two-site assays
(Fig. 4). The suggestion in Fig. 1 from the anti-PC/anti-
PCassaythatsomeplacentalproductscontainmorethan
one PC epitope is conﬁrmed in Fig. 4 as shown by the
greater absorbance achieved in the anti-PC/anti-
(pro)CRF assay of the later eluting proCRF broad peak
(fractions 55–65; Fig. 4a) when compared with the anti-
PC/NKB versus proNKB (fractions 54–64; Fig. 4b) where
the absorbance readings across the broad peak in each
assay is similar. This suggests again (Fig. 1)t h a tp r o C R F
contains more than one PC PTM, whereas proNKB has
onlyone.Asdimeric(bA–bA)activinA(peakfraction41,
Fig. 4c) did not coincide with any of the anti-probA/anti-
PCreactivepeaks,thissuggeststhatpro-activindoescarry
PC as a PTM but the fully processed (bA–bA) placental
form does not.
The ﬁrst rat placental NKB peak from the C3 HPLC
(fractions 33–34), which was reactive in both NKB/NKB
and PC/NKB assays, also eluted as a single peak with a
Kav of 0.45 when subjected to Superdex gel ﬁltration
suggesting that it is the same as human placental NKB.
In order to investigate the mode of attachment of PC
to placental prohormones we pooled fractions 40–45
and 51–55 separately and monitored the change of
immunoreactivity in each pool using the proCRF,
activin, PC/proCRF and PC/pro-activin two-site immu-
noassays after digestion with endoglycosidase or PLC.
Figure 3 SDS-PAGE of selected fractions resulting from the
preparative C3 HPLC of a rat placental extract. Coomassie blue-
stained gel is shown in (a), the anti-PC IgG western immunoblot in
(b) and the merged image in (c) in which only a limited number of
coomassie stained bands are PC immunoreactive.
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immunoreactivity in both proCRF/CRF and
PC/proCRF immunometric assays signal after deglyco-
sylation (Fig. 5). Given the previous evidence for
reduced binding seen in the anti-proCRF and anti-PC
tracks of the 30 kDa band (Fig. 2b), the increase in
immunoreactivity was not unexpected and conﬁrmed
that removal of the bulky polysaccharide PTM(s) from
proCRFwouldallowantibodies(raisedoriginallyagainst
a short synthetic proCRF peptide or PC coupled to
carrier proteins) better access to their respective
epitopes in the precursor proCRF backbone. However,
there was a very signiﬁcant reduction in signal after PLC
digestion of both pools as measured by the proCRF/PC
andbAsubunit/PCtwo-siteassays.Theredidnotappear
tobeanyinterferenceofcontaminatingproteaseactivity
resulting from any of these enzyme digestions given the
absence of any loss of immnuoreactivity in the anti-
proCRF/CRF and anti-activin A (bA–bA) results versus
controls.
Discussion
It is known that the PC group found on the ﬁlarial
nematode secretory protein ES-62 is attached to the
N-N-acetyl glucosamine atthe end of a complex N-linked
polysaccharidemoietyPTM(Haslametal.1997);thus,the
s p e c i ﬁ cm o d eo fa t t a c h m e n to fP Ct op l a c e n t a lp o l y -
peptide hormones will require further examination.
However, the literature may provide some clues as to the
identityoftheenzymeinvolved.CTP:PCcytidylyltransfer-
ase a is a ubiquitous enzyme, it has a nuclear transfer
signalmotifandcatalysestherate-limitingstepduringthe
introduction of PC into phosphatidylcholine during
membrane formation in all cells throughout the body. A
second PC transferase gene, however, was discovered in
1998(CTP:PCcytidylyltransferaseb(Lykidisetal.1998)).
It predicts an enzyme with a similar catalytic motif but
lacks the nuclear transfer motif and seems to be
associated with the endoplasmic reticulum (Lykidis et al.
1998), the site of translation and synthesis of proteins
destined for secretion. Interestingly, this enzyme is
strongly expressed in the placenta, and to some extent
in the testis, with little expression in all other tissues
examined (Lykidis et al. 1998, 1999), and thus is a prime
candidate to play a role in PC modiﬁcation of placental
secretory peptides and proteins. The placenta and testis
are similar in that they are both immune-privileged sites.
Thisisbiologicallynecessaryforthesuccessofpregnancy
and to protect germ cells from autoimmune attack. In
immune-privileged sites the systemic immune apparatus
Figure 4 Comparison of PC containing neuropeptide with neuropeptide immunoreactivity in fractions from
the HPLC of the rat placental extract. Fractions 30–65 from the preparative HPLC step in Fig. 3 were
submitted to a number of two-site ELISAs. –>– represents two-site anti-neuropeptide/anti-neuropeptide
assay results in each case. All ELISA protocols were the same as described in Materials and methods; (a)
proCRF,in (b)NKB,in(c)activinAand (d)hemokinin.–C– represents theresultsoftwo-siteimmunometric
assays with the anti-neuropeptide antibody being in (a) anti-proCRF (1–21) IgG, (b) anti-NKB(1–5) IgG, (c)
anti-probA subunit IgG and (d) anti-HK(1–5) IgG in combination with anti-PC IgG in each case.
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environment is maintained. The close association
between the steroidogenic (testosterone secreting)
Leydig cells and interstitial testicular macrophages
suggests that these cells are functionally related (Hales
2002).
From the results presented in this study, it would
appear that a large number of the polypeptides and
proteins synthesised by the placenta carry PC as a tissue-
speciﬁc PTM. In placental NKB, the PC would appear to
be attached via the aspartate side chain at position 4.
However, despite many repeated experiments, we have
been unable to obtain any unequivocal mass spectro-
metric analysis with either rat or human puriﬁed
placental NKB. This is due to the miniscule amount of
storedmatureNKBintheplacentaandthefactthatithas
been found that mass spectrometric analysis of PC-sub-
stituentpeptidesarehamperedbythiszwitterionicgroup
resulting in low sensitivity and unusual fragmentation
ions apart from the ﬁnal products, choline and PC
(Grabitzkietal.2005). The observationsthatPCattached
to placental NKB only causes a small decrease in Kav
during gel ﬁltration, PC-proCRF has a relatively small
molecular weight (15 kDa) and endoglycosidase treat-
mentofglycosylatedPC-proCRFdoesnotremovethePC,
would suggest that the mode of attachment in the
placenta is more simple than that seen in the large
polysaccharide complex of ES62. Given the phospho-
lipaselabilityofPCattachedtoplacentalpeptidesandthe
strong expression in the placenta of the CTP:PC
cytidylyltransferase, we would speculate that PC is
attached to NKB and proCRF (and by analogy other
placental peptide hormones) via a short linker such as
glycerol (cf. phosphatidyl choline and platelet activating
factor). Alternatively PC could be attached directly via a
high-energy labile mixed anhydride to the side chain of
aspartyl residues or via ester bonds to hydroxyl side
chains. However, the latter are not present in mature
NKB.
The presence of PC groups on placental secretory
proteins and peptides could therefore play a major role,
at low concentrations, in modulating the maternal
immune system (as in the case of parasitic nematode
infection (Harnett et al. 2003)) and assisting in the
evasion ofthe mother’simmunesurveillance. Milleretal.
(1991) hypothesised that as ES-62 promoted parasitic
survival by stimulating the secretion of antibodies which
did not damage the adult helminth. This function of PC
coupledtoplacentalproteins(secretedorexposedatthe
placental/uterine interface) may also reduce anti-
placental-directed antibody production. Additionally as
the phosphocholinated ﬁlarial parasitic protein (ES-62)
at high concentrations (O20 mg/ml) is mitogenic for
B-cells in vitro (Harnett & Harnett 1993), the increasing
concentrations of placental PC-containing polypeptides
in maternal blood towards term might be expected to
lead to a similar increase in B-cell activity. If there is such
anincrease inthe blood concentrationsofthe repertoire
of maternal protective antibodies during the third
trimester then it would help their placental transfer
through the placental syncytiotrophoblast (Leach et al.
1996) via fetal Fc receptor, a key process necessary for
neonatal immunity (Simister 2003).
The PC moieties present on many placental
polypeptide hormones as seen in the many immun-
reactive bands in Fig. 3 may be attached to the
peptide backbone such that the normally PC-unmo-
diﬁed (immunoreactive) epitopes that take part in
currently available immunoassays designed to detect
the normal peripheral and brain ﬁnal processed
forms are rendered non-reactive by this highly
charged group. This has been found to be the case
with placental NKB, as we have observed that the ﬁnal
placental processed form (unlike brain/synthetic
NKB) cross-reacts weakly with several in-house and
Figure 5 The effect of enzyme treatment on the immunoreactivity
of pro-CRF-PC and pro-bA-PC. Peak one represents a pool of
fractions 36–37 and peak two, a pool of fractions 41–43 from
Fig. 4, which were freeze-dried separately before being recon-
stituted in assay buffer. Open histogram represents ELISA assay
result with no enzyme treatment, black histogram after phospho-
lipase C digestion and grey histogram after endoglycosidase
digestion. Values are the means of duplicate determinations in the
respective two-site immunometric assay.
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the anti-PC antibody. Since our original report
suggesting that many of the symptoms of pre-eclamp-
sia could be explained by progressive stimulation of
the three neurokinin receptors by increasing
secretion of NKB by the placenta (Page et al. 2000);
lung and liver oedema (Grant et al. 2002) and a
decrease in placental antioxidant defences (Sawicki
et al. 2003) have been added to the list of NKB-
induced conditions. The effect of this highly charged
PC group on the biological activity of NKB at
neurokinin (NK3R) and other receptors (e.g. the
PC-platelet activating factor receptor and PC-inﬂam-
matory receptors) during pregnancy particularly in
the pathogenesis of pre-eclampsia must await
complete characterisation and synthesis of placental
phosphocholinated NKB. However, if PC-NKB does
have potent activity at the NK3R, it may explain why
senktide, a synthetic neurokinin analogue, has been
used in NK3 receptor agonist studies rather than the
synthetic brain form of NKB, which is a relatively
poor/partial agonist at its ‘preferred receptor’
(NK3R) found predominantly in the periphery
(Wormser et al. 1986).
Thisstudy isthe ﬁrsttoidentify proCRFand its mature
peptide inthe ratplacenta.Althoughourresultsindicate
that in the rat, placental CRF remains predominantly
unprocessed as a phosphocholinated precursor proCRF
and itsglycosylatedforms,someprocessingdoesoccuras
demonstrated by the 4.5 kDa band (the size of mature
CRF) seen in the anti-CRF track (Fig. 2) and is free of
PC-immunoreactivity. The placental extract immuno-
blots probed with anti-CRF, anti-proCRF and anti-PC
antibodies all demonstrate a number of intermediate
processed forms, suggesting that the placenta contains
endopeptidasescapable ofprocessingproCRF. Asourrat
placental tissue extractions were carried out rapidly at
strong acidic pH, minimal protein degradation would be
expected, suggesting these intermediate forms are not a
consequence of adventitious degradation during tissue
processing. The difference in the size and band intensity
of the proteins will reﬂect not only the differential
processing of the proCRF precursor but also the varying
number PC-PTMs and the size and complexity of sugars
moieties at N-linked glycosylation sites and their proxi-
mity to the anti-proCRF and anti-PC epitopes. Increased
processing of proCRF has, however, been demonstrated
in pre-eclampsia placentae when compared with normal
termplacentae(Ahmedetal.2000)an dwashypoth esised
to be related to damage in vivo associated with pre-
eclampsia placental pathology.
After demonstrating that the rat placenta contained
substantial amounts of proCRF, we explored whether
these forms are secreted and circulate in the maternal
blood and have demonstrated that CRF is present in rat
pregnancy plasma, although it appears mainly present
as phosphocholinated proCRF and its glycosylated
forms suggesting the precursors are the dominant
circulating forms during pregnancy in the rat. In the
human, although there is evidence for unprocessed
proCRF inearly pregnancyit ismainly fully processed to
mature CRF towards term (Sanderson et al. 2000). The
low signal seen in Fig. 1a with human-term placental
extracts in the proCRF/CRF two-site assay is in
agreement with this. It is interesting to note that
more heterogeneity was evident in the immunoblots of
rat placental extracts than in the secreted forms found
in plasma suggesting maturation, PC and polysacchar-
ide addition are late events during processing within
the placenta. The fact that the processed forms of
proCRF in the plasma contain PC as a PTM suggests
that PC plays an important function during pregnancy
and may be the reason for the elevated levels of
C-reactive protein (Tjoa 2003) and the accompanying
inﬂammation seen in this condition (Redman et al.
1999). Additionally, once the behaviour of this PTM has
affected the immunological detection and biological
activity of a variety of placental polypeptide hormones
has been revealed, increased recognition of its presence
and role played when attached to each placental
hormone may lead to a new era of placental
physiology/pathology.
There are perhaps other situations in which
PC-containing proteins take part in physiology and
disease. It may be no coincidence that, whereas
CTP:PC cytidylyltransferase-b expression is very low
in most peripheral tissues, it could be easily detected
in the cytoplasm of HeLa cells (Lykidis et al. 1998).
Downregulation of the immune system is an import-
ant step during the genesis of some tumours; thus the
detection of tumour cell-surface/secretory proteins
could be useful in early cancer diagnosis and
inhibiting the enzyme(s) involved in PC attachment
to proteins could form part of tumour therapy.
Another important area in which PC may play a role
is arthritis, as recently it has been demonstrated that
administration of the ﬁlarial nematode secretory
glycoprotein ES-62 can reverse the experimentally
induced condition in mice (McInnes et al. 2003).
Thus, the possibility that the remission of rheumatoid
arthritis often seen in pregnancy may be due to the
effects of some circulating placental PC-containing
peptides, suggests that the use of simple PC-peptide-
like compounds should be considered for treating this
condition. Similar compounds could also be used
to stop recurring miscarriage when it is a consequence
of enhanced immune intolerance during early
pregnancy.
Finally, if tissue expression of PC proteins allows
placental survival then engineering stem cells destined
for transplant therapy to express this property may
constitute a universal transplant strategy.
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